Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Naratriptan: an alternative for migraine.

D A Dulli1

  • 1Department of Neurology, Medical School, University of Wisconsin, Clinical Science Center, Madison 53792, USA. dulli@neurology.wisc.edu

The Annals of Pharmacotherapy
|July 20, 1999
PubMed
Summary

Naratriptan offers a promising new oral treatment for acute migraine headaches. It demonstrates good tolerability and may benefit patients who experience side effects with other triptan therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ischemic stroke in young adults: Results from the university of Wisconsin stroke registry.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2015
Same author

Anticardiolipin antibodies in a university hospital population.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2015
Same author

Relationship between age and mortality due to intracerebral versus subarachnoid hemorrhage.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2007
Same author

Differing mechanisms between posterior and middle cerebral artery infarctions.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2007
Same author

Ischemic stroke associated with activated protein C resistance and aortic valvular papillary fibroelastoma.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2007
Same author

Pulsatile tinnitus in cerebrovascular arterial diseases.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2007

Area of Science:

  • Pharmacology
  • Neurology
  • Gastroenterology

Background:

  • Migraine treatment has advanced with triptans and serotonin agonists.
  • Oral triptans can have adverse effects and lead to migraine recurrence.
  • Naratriptan is a new oral option for acute migraine therapy.

Purpose of the Study:

  • To evaluate naratriptan's clinical pharmacology, efficacy, and safety.
  • To compare naratriptan with other oral triptan therapies.
  • To assess naratriptan's indications for migraine treatment.

Main Methods:

  • Conducted a MEDLINE search from January 1990 to June 1998.
  • Reviewed articles on naratriptan, triptans, and serotonin agonists.
  • Critically assessed clinical trials and product information for naratriptan and other oral triptans.

Main Results:

  • Two Phase III trials showed 60-68% of patients achieved relief at four hours with 2.5 mg naratriptan.
  • Migraine recurrence at 24 hours was observed in 27-28% of patients, similar to other oral triptans.
  • Naratriptan's adverse effects were comparable to placebo, with superior tolerability versus other oral triptans.

Conclusions:

  • Naratriptan is a promising oral therapy for acute migraine.
  • It may be suitable for patients intolerant to other triptans.
  • Naratriptan could be effective for longer migraine headaches.

Related Experiment Videos